Nothing Special   »   [go: up one dir, main page]

Brackenbury et al., 2008 - Google Patents

Voltage-gated Na+ channel β1 subunit-mediated neurite outgrowth requires Fyn kinase and contributes to postnatal CNS development in vivo

Brackenbury et al., 2008

View PDF @Free from Publisher
Document ID
672313512255081576
Author
Brackenbury W
Davis T
Chen C
Slat E
Detrow M
Dickendesher T
Ranscht B
Isom L
Publication year
Publication venue
Journal of Neuroscience

External Links

Snippet

Voltage-gated Na+ channel β1 subunits are multifunctional, participating in channel modulation and cell adhesion in vitro. We previously demonstrated that β1 promotes neurite outgrowth of cultured cerebellar granule neurons (CGNs) via homophilic adhesion. Both …
Continue reading at www.jneurosci.org (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells

Similar Documents

Publication Publication Date Title
Brackenbury et al. Voltage-gated Na+ channel β1 subunit-mediated neurite outgrowth requires Fyn kinase and contributes to postnatal CNS development in vivo
Zaltieri et al. α-synuclein and synapsin III cooperatively regulate synaptic function in dopamine neurons
Andzelm et al. Myosin IIA is required for cytolytic granule exocytosis in human NK cells
Eroglu et al. Gabapentin receptor α2δ-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis
Tian et al. Antagonistic regulation of actin dynamics and cell motility by TRPC5 and TRPC6 channels
Jones et al. Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats
Petersen et al. The adhesion GPCR GPR126 has distinct, domain-dependent functions in Schwann cell development mediated by interaction with laminin-211
Somasundaram et al. Store-operated CRAC channels regulate gene expression and proliferation in neural progenitor cells
Zaman et al. The role of impaired mitochondrial dynamics in MFN2-mediated pathology
Elmer et al. MHCI requires MEF2 transcription factors to negatively regulate synapse density during development and in disease
Pavlowsky et al. A postsynaptic signaling pathway that may account for the cognitive defect due to IL1RAPL1 mutation
Wu et al. Inhibition of TRPC1-dependent store-operated calcium entry improves synaptic stability and motor performance in a mouse model of Huntington’s disease
Li et al. αE-catenin inhibits YAP/TAZ activity to regulate signalling centre formation during tooth development
Su et al. KIF5B promotes the forward transport and axonal function of the voltage-gated sodium channel Nav1. 8
Tejero et al. Synaptotagmin-2, and-1, linked to neurotransmission impairment and vulnerability in Spinal Muscular Atrophy
Cramer et al. Cross-talk between GABAergic postsynapse and microglia regulate synapse loss after brain ischemia
Thei et al. Microglia in alzheimer's disease: a role for ion channels
Dinamarca et al. Ring finger protein 10 is a novel synaptonuclear messenger encoding activation of NMDA receptors in hippocampus
Weiss et al. Trafficking of neuronal calcium channels
Sepers et al. Endocannabinoid-specific impairment in synaptic plasticity in striatum of Huntington's disease mouse model
Lasser-Katz et al. Mutant α-synuclein overexpression induces stressless pacemaking in vagal motoneurons at risk in Parkinson's disease
Burns et al. Recovery of respiratory function in mdx mice co‐treated with neutralizing interleukin‐6 receptor antibodies and urocortin‐2
Montani et al. Neuropeptide Y in the olfactory microvillar cells
Gattlen et al. The inhibition of Kir2. 1 potassium channels depolarizes spinal microglial cells, reduces their proliferation, and attenuates neuropathic pain
Tae et al. Gabapentin modulates HCN4 channel voltage-dependence